A RANDOMIZED PHASE 3 STUDY OF SITRAVATINIB IN COMBINATION WITH NIVOLUMAB VERSUS DOCETAXEL IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WITH DISEASE PROGRESSION ON OR AFTER PLATINUM-BASED CHEMOTHERAPY AND CHECKPOINT INHIBITOR THERAPY (SAPPHIRE)

Registry ID

516-005

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

MIRATI THERAPEUTICS INCORPORATED

Start date

2021-12-07

Completion date

2024-10-16

Last update

2020-06-19

Conditions

• NON-SQUAMOUS/SQUAMOUS NSCLC

Related clinical trials

• BEAMION PANTUMOR-1: A PHASE II, MULTICENTRE, MULTICOHORT, OPEN LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZONGERTINIB (BI 1810631) FOR THE TREATMENT OF SELECTED HER2-MUTATED OR OVEREXPRESSED/AMPLIFIED SOLID TUMOURS
• A PHASE III, RANDOMISED, OPEN-LABEL, GLOBAL STUDY OF DATOPOTAMAB DERUXTECAN (DATO-DXD) IN COMBINATION WITH RILVEGOSTOMIG (AZD2936) OR RILVEGOSTOMIG MONOTHERAPY VERSUS PEMBROLIZUMAB MONOTHERAPY FOR THE FIRST-LINE TREATMENT OF PARTICIPANTS WITH LOCALLY-ADVANCED OR METASTATIC NON-SQUAMOUS NSCLC WITH HIGH PD-L1 EXPRESSION (TC ¿ 50%) AND WITHOUT ACTIONABLE GENOMIC ALTERATIONS (TROPION-LUNG10)
• A RANDOMIZED PHASE 3 STUDY OF DATOPOTAMAB DERUXTECAN (DATO-DXD) AND PEMBROLIZUMAB, WITH OR WITHOUT PLATINUM CHEMOTHERAPY, IN SUBJECTS WITH NO PRIOR THERAPY FOR ADVANCED OR METASTATIC PD-L1 TPS <50% NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WITHOUT ACTIONABLE GENOMIC ALTERATIONS (TROPION-LUNG07)

View on source registry